Patent Application
20190328891
The invention relates to a medical preparation with a carrier based on hyaluronan and/or its derivatives where the carrier used directly carries the active agent and is present in various forms. The invention also relates to a method of preparing, and the use of, said medical preparation.
Hyaluronic acid (hyaluronan, HA) is known as a non-sulphated glycosaminoglycan composed of two repeating units of D-glucuronic acid and N-acetyl-D-glucosamine, linked via β(1→4) and β(1→3) glycosidic bonds, see
In view of the fact that this polymer is biocompatible, inherent to the body, and degradable, it becomes a suitable substrate for tissue engineering or as a carrier of bioactive substances (Schante C. E. et al.: Carbohyd Polym 85, 469 (2011)).
The use of hyaluronan and its derivatives with modified or improved properties in the field of medicine is quite wide. Chemical modification of hyaluronan is usually preformed in two reaction centres: on the carboxyl group and on the primary hydroxyl group. An amino group can also be used after cleavage of N-acetyl group. It is not clear which of the hydroxyl group of the saccharide unit participates in the reaction; many results indicate the preference of the primary hydroxyl (C6) of the N-acetylglucosamine unit because of the highest reactivity of this group.
The carboxyl group can be converted into an amide or an ester. Activating agents conventionally used for chemical preparation of peptides, such as carbodiimides (see, e.g. Danishefsky I. et al. Carbohyd Res 16 (1), 199 (1971); Bulpitt P. et al. J Biomed Mater Res 47 (2), 152 (1999); Foullain N. et al., Carbohyd Polym 74 (3), 333 (2008); and Oh E. et al. J Control Release 141 (1), 2 (2010)) or other agents, such as 2-chloro-1-methylpyridiniumiodide (see, e.g. Magnani A. et al. Polym Advan Technol 11 (8-12), 488 (2000)), 2-chloro-dimethoxy-1,3,5-triazine (see, e.g. Bergman K. et al. Biomacromolecules 8 (7), 2190 (2007)), carbonyldiimidazole (see, e.g. WO 2000/001733) etc., can be used for the conversion of the carboxyl group to an amide. After increasing the carboxyl reactivity through conversion into a more reactive intermediate, an amine is added to provide an amide by a condensation reaction. An ester can be formed by an alkylation reaction with alkylhalogenides (see, e.g. U.S. Pat. No. 4,851,521 and Pelletier S. et al. Carbohyd Polym 43 (4), 343 (2000)), via methyl ester synthesis by reaction with diazomethane (see, e.g. Jeanloz R. et al. J Biol Chem 186 (2), 495 (1950) and Hirano K. et al. Carbohyd Res 340 (14), 2297 (2005)), via use of an epoxide (see, e.g. Leach J. et al. Biotechnol Bioeng 82 (5), 578 (2003); Bencherif S. et al. Biomaterials 29 (12), 1973 (2008); Weng L. et al. Biomaterials 29 (14), 2153 (2008); and Prata J. et al. Biomacromolecules 11(3), 769 (2010)), etc.
The modification of a hydroxyl group leads to the formation of an ether or an ester bond. Ethers can be easily prepared by the reaction with epoxides (see, e.g. Laurent T. et al. Acta Chem Scand 18 (1), 274 (1964); Yui N. et al. J Control Release 22 (2), 105 (1992); Tomihata K. et al. Biomaterials 18 (3), 189 (1997); and WO 2000/046253), divinylsulphones (see, e.g. U.S. Pat. No. 4,582,865; Ramamurthi A. et al. J Biomed Mater Res 60 (1), 196 (2002); and Eun J. et al. J Biomed Mater Res-A 86 (3), 685 (2008)), ethylensulphides (see, e.g. Serban M. et al. Biomaterials 29 (10), 1388 (2008)), or by formation of a hemiacetal with the use of glutaraldehyde (see, e.g. Tomihata K. et al. J Polym Sci Pol Chem 35 (16), 3553 (1997) and Crescenzi V. et al. Carbohyd Polym 53 (3), 311 (2003)). Symmetric or mixed anhydrides can be used for an ester synthesis (see, e.g. CZ302856, WO/2014/082609, and Huerta-Angeles G. et al. Carbohyd Polym 111, 883 (2014)), and O-acyl-O′-alkylcarbonate may be used as an activating agent (see, e.g. WO 2010/105582). These structural modifications lead to a crosslinking reaction to form hydrogels.
Solid Phase Peptide Synthesis, SPPS, is a method where individual amino groups are gradually linked to a polymer carrier. Protecting groups (permanent or temporary) are used for all amino acids to decrease the risk of side reactions and formation of undesirable sequences. Protecting groups such as Fmoc and Boc are the most frequently used, where Fmoc protecting group can be cleaved in a basic environment and Boc protecting group can be cleaved in an acid environment. Solid phase peptide synthesis comprises repeating of the cycles of “condensation-washing-cleavage of protecting groups-washing”. A synthetized peptide remains anchored to the polymer carrier until its desired sequence is obtained. Then a cleavage from the carrier and purification are performed.
Nowadays there is an effort to use carriers that can be biocompatible and optionally biodegradable. The carriers based on polysaccharides from alginate, agar, chitin, hyaluronan or cotton have been described. So far, the peptides have always been cleaved from the carriers. The beneficial biological properties, that can mutually positively influence the biological properties of the peptide (see, e.g. Eichler J. et al.: Cotton-carrier for solid phase peptide synthesis (1991) and WO 2012/101612) synthetized or anchored on the carrier, have not been used.
Alginates are the most common carriers used for the reaction of peptides and amino acids with polysaccharides. Alginate is a linear negatively charged polysaccharide consisting of repeating monomer units of β-D-mannuric acid and α-L-guluronic acid linked via (1-4) O-glykosidic bonds, as it is shown in the structural formula of the alginate in Figure. 2.
The use of alginate as a drug form for pharmaceuticals was described; however the processes were most often used for non-covalent anchoring of these drugs in a matrix or a gel. The alginate gel has been used also for analytical procedures of capturing the high molecular peptides, mainly enzymes, cell organelles, or the whole cells (see, e.g. Palmieri G. et al. J Chromatogr B 664, 127 (1995) and Morgan S. M. et al. Int J Pharm 122, 121 (1995)).
Covalent bonding of peptides and drugs enables their use as sophisticated dosage systems enhancing pharmacokinetics and bioavailability which enhances the clinical potential of a drug. The conjugate alginate-peptide is formed by an amidic bond between the carboxyl group of the alginate and the amino group of the peptide (see, e.g. Palmieri (1995); Morgan (1995), and Hashimoto T. et al. Biomaterials 25, 1407 (2004)).
The alginates with covalently bound peptides can be used in treatment of an injury. Wound healing includes a tissue reaction to an injury. It is a complicated biological process comprising chemotaxis, cell proliferation, production of extracellular proteins, neovascularization etc. One of the possibilities of wound healing treatment is influencing the healing process by natural stimulation agents such as growth factor (see, e.g. Hashimoto (2004)).
Materials based on alginates have been prepared, which were modified by a peptide, and their effectivity in the wound healing process was studied on the injured skin in vivo. Rabbits treated with an alginate bandage containing a hybrid peptide Ser-Ile-Arg-Val-X-Val-X-Pro-Gly (where X=Ala or Gly) showed significantly higher epithelization and larger volume of regenerated tissue in comparison with other peptides Ser-Ile-Lys-Val-Ala-Val and Val-Pro-Val-Ala-Pro-Gly that were also anchored on the alginate bandage (see, e.g. Hashimoto (2004)).
Cellulose in the form of paper was also used for the preparation of peptides. From a chemical point of view, cellulose is a linear polysaccharide consisting of repetitive monomer units of d-glucose linked via β(1→4) O-glycosidic bonds, according to the structural formula shown in
Cotton is the purest form of cellulose, excepting microbial cellulose, and can be obtained in various forms and shapes; the possibility of the use of cotton as the carrier for SPPS has been studied. In this case, the anchoring of the peptide was performed by means of an ester bond between the hydroxyl group of cotton and the carboxyl group of the peptide. The synthesis was most often performed in DIC/HOBt/DMAP in DMF (see, e.g. Eichler et al. “Cotton-carrier for solid phase peptide synthesis” (1991); Pept Res 4 (5), 296 (1991); and “Innovation and Perspectives in Solid Phase Synthesis,” Birmingham, UK: SPCC, 337-343 (1990)).
Nowadays, carriers based on hyaluronan in the form of fibres (see, e.g. WO 2012/089179, WO 2013/167098, WO 2014/082610, and WO 2014/082611), thin films (see, e.g. WO 2016/141903 and Foglarová M. et al. Carbohydr Polym 144, 68 (2016)), or nonwoven fabrics (see, e.g. WO/2013/167098) are available. The use of these perspective forms could remove some of the described drawbacks of the polysaccharide carriers used so far. However, there is still a lack of suitable carriers of pharmaceutical drugs.
The new method described herein has the advantage of the use of a carrier based on hyaluronan in the form of fibres, thin films, or nonwoven fabrics for solid-phase synthesis. This carrier does not change during the reaction, i.e., it remains in the form of fibres, thin films, or nonwoven fabrics. Thus, it is a solid-phase synthesis where the peptide is constructed by individual amino acids or it is linked, as a whole, to the hyaluronan material. So far, hyaluronan has been used for the modification in solution, i.e., hyaluronan was dissolved and the reaction performed.
Then the derivative was used for the preparation of the material. The difference between liquid-phase and solid-phase synthesis is that in case of solution synthesis and subsequent spinning, the peptide is also present inside the fibre, so it is less available. The solid-phase synthesis saves costs, and the peptide being on the surface only spares from the optimization of the spinning processes which are different for individual derivatives.
In particular, the abovementioned drawbacks are solved by a method of preparing a medical preparation with a carrier based on hyaluronan and/or derivatives thereof, and by the medical preparation with the carrier based on hyaluronan and derivatives thereof, as described herein and defined in the appended claims.
The medical preparation comprises a conjugate of hyaluronic acid and derivatives thereof with a medical substance, according to the general formula (X):
A-S—N (X),
or the formula:
where
each A is the medical substance selected from the group comprising amino acids and peptides,
each S is a method of linking (i.e., a linker/linking group, e.g. a divalent linking group) of the medical substance with the carrier and comprises —O— or —NH—,
In some embodiments, the carrier of the medical preparation, alternatively the medical preparation itself, is water-insoluble and biodegradable.
In certain embodiments, the medical preparation is prepared without the carrier being dissolved. In other words, the carrier remains insoluble during the whole preparation process, i.e., in solid phase, wherein at the same time it maintains its biodegradability.
In particular embodiments, the medical preparation comprises the carrier in the form of an endless fibre, thread, fabrics, thin film, staple fibre and/or nonwoven textile.
In specific embodiments, the medical preparation comprises the medical substance bonded onto the carrier in the position 6 of the glucosamine part of the conjugate of hyaluronic acid and/or its derivatives according to the general formula X.
In some embodiments, the medical substance is anchored to hyaluronic acid and/or its derivatives via an ester bond (e.g. according to Scheme 1 below) or by reductive amination (e.g. according to Scheme 2 below).
In some embodiments, the carrier comprises, alternatively is, hyaluronic acid, palmitoyl hyaluronan, or formyl hyaluronan. In these or other embodiments, the carrier has a molecular weight in the range of from 1.5×104 to 2.5×106 g·mol−1.
As introduced above, this disclosure also provides a method of preparing the medical preparation with a carrier based on hyaluronan and/or its derivatives where the carboxyl group of an amino acid or peptide in the medical substance A, which comprises an N-terminal protecting group (i.e., a terminal N-protecting group), is activated with a condensation agent in an aprotic polar solvent to form a reactive intermediate I, which reacts with the carrier in the presence of an organic base and a catalyst to form a conjugate of hyaluronic acid and/or derivatives thereof with the medical substance. Thereafter, the terminal N-protecting group of the medical substance is cleaved off in a basic medium. Typically, the basic medium is selected from a group consisting of, 20% piperidine in N,N-dimethylformamide, 2% 1,8-diazabicyclo[5.4.0]undec-7-ene in N,N-dimethylformamide, and 30% tert-butylamine in N,N-dimethylformamide. In specific embodiments, the basic medium comprises, alternatively is, 20% piperidine in N,N-dimethylformamide.
The medical substance A is typically selected from the group consisting of amino acids and peptides (i.e., the medical substance A comprises an amino acid and/or a peptide). The medical substance A is linked to the carrier directly, or via a linear linker based on a peptide formed by hydrophobic amino acids Xaa, such as Xaa-Ahx-Ahx-Xaa.
In some embodiments, the method comprises forming the conjugate of hyaluronic acid and/or its derivatives at a temperature of from 20° C. to 40° C., such as at a temperature of from 22° C. to 25° C., for a time of from 2 to 48 hours, such as for 24 hours.
The condensation agent utilized in the method is typically selected from the group of 4-nitrophenol, N-hydroxy succinimide, 2,4,5-trichlorophenol, 2,3,4,5,6-pentafluorophenol, 2,3,4,5,6-pentachlorophenol, N,N′-diisopropyl carbodiimide, N,N′-dicyclohexyl carbodiimide, l-[bis(dimethylamino) methylen]-1H-1,2,3-triazolo[4,5-b] pyridinium3-oxide hexafluoro phosphate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, ethylchloroformiate, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium hexafluoro phosphate, benzotriazol-1-yl-oxy-tris(dimethylamino)-phosphonium hexafluoro phosphate, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyl uronium tetrafluoro borate, 4-triethylamino-dicyclohexyl karbodiimide p-toluensulphonate, and propyl phosphonic acid anhydride. In specific embodiments, the condensation agent comprises, alternatively is, N,N′-diisopropyl carbodiimide.
The polar aprotic solvent utilized in the method is typically selected from the group comprising N,N-dimethyl formamide, dimethyl sulphoxide, N-methyl-2-pyrrolidone, acetonitrile, dichloromethane, tetrahydrofuran, and 1,4-dioxane. In certain embodiments, the polar aprotic solvent comprises, alternatively is, N,N-dimethyl formamide.
The organic base utilized in the method is typically selected from the group comprising triethylamine, pyridine, morpholine, N-methyl morpholine, N,N′-diisopropyl ethylamine, and imidazole.
The catalyst utilized in the method is typically selected from the group comprising ethyl (hydroxyimino) cyanoacetate, hydroxyl benzo triazole, N,N-dimethyl amino pyridine or 1-hydroxy-7-azabenzo triazole. In some embodiments, the catalyst comprises ethyl (hydroxyimino) cyanoacetate and/or N,N-dimethyl amino pyridine.
The method according to the invention is also characterized in that the amount of the amino acid or peptide used, i.e., in/as the medical substance, corresponds to from 1 to 5 equivalents, alternatively 3 equivalents, based on the dimer of hyaluronic acid and/or its derivative(s); the amount of the activating (condensation) agent used corresponds to from 0.1 to 5 equivalents, alternatively 3 equivalents, based on the dimer of hyaluronic acid and/or its derivative(s); the amount of the base used corresponds to up to 10 equivalents, based on the dimer of hyaluronic acid and/or its derivative(s); and the amount of the catalyst used corresponds to from 0.1 to 5 equivalents, alternatively 3 equivalents of ethyl (hydroxyimino) cyanoacetate and 0.3 equivalents of N,N-dimethyl amino pyridine, per dimer of hyaluronic acid and/or its derivative(s). In particular embodiment of the invention, the molar ratio of the medical substance, condensation agent, catalyst, and hyaluronic acid dimer is 1:1:1:1, respectively.
The medical preparation in the form of the conjugate, according to the invention is for medical use as a dosage form of an active peptide or amino acid, intended for dermal, sublingual, oral, buccal, or local administration into an open wound.
For example, in certain embodiments the medical preparation according to the invention is for dermal administration and can contain, for example, the peptide Dalargin as the medical substance. In some embodiments, the medical preparation according to the invention is for buccal or sublingual administration and can contain, for example, a peptide selected from the group of Desmopressin, Lysipressin, and Glypressin, as the medical substance. Likewise, the medical preparation according to the invention for buccal administration can contain, for example, a peptide selected from the group of antiviral drugs and adjuvants, and releasing factor for luteinizing and/or follicle-stimulating hormone. In some embodiments, the medical preparation according to the invention is for direct administration to an open wound and can contain, as the medical substance, for example, a peptide selected from the group of Glypressin, Dalargin, and AdDP (e.g. as an immunostimulant).
Thus, one aspect of the invention according to certain embodiments is the new compounds of the general formula (X):
A-S—N (X),
where the solid carrier N is made of hyaluronan and/or its derivatives in the form of an endless fibre, thread, fabric, thin film, staple fibre and nonwoven fabric comprising the medical substance A linked by means of linkage S, and the method of the preparing this complex system by the procedure in solid phase, or by bonding the medical substance into a complex system, as described herein and illustrated in the examples below.
In certain embodiments, the method of linking the medical substance with the carrier is performed via esterification (e.g. by formation of an ester bond) or by reductive amination. The carrier is a biocompatible and biodegradable solid carrier characterized in that it does not need to be cleaved from the medical substance during its various, mainly medical (i.e., bioactive), activities, and that it can further act as a modern non-invasive dosage form facilitating the penetration of biologically active peptides or amino acids bound on said biocompatible carrier through mucosa and skin, and thus it serves as a complex and suitable material used for medical applications in human and veterinary medicine. The medical preparation according to the invention acts as a whole during the biological activity and the medical substance can be released slowly, in a prolonged manner from the carrier, which is subsequently eliminated naturally and intrinsically. The carrier can also affect the total effect of the medical substance bonded thereon and facilitate its use.
Table 1 presents peptides and their medical effect and the method of their administration, which can be utilized in the medical preparation and related methods of this disclosure. More specifically, it shows that the medical preparation according to the invention for dermal administration comprises peptide Dalagrin as the medical substance having a healing effect, or Oxytocin having hormonal effect. For oral, buccal or sublingual administration, the medical preparation according to the invention comprises the peptide Desmopressin showing an antidiuretic effect, influence on blood coagulation by increasing the VIII factor, Lysipressin having presoric effect mainly in dental surgery, or Glypressin (Terlipressin) with a prolonged pressoric effect suitable to stop bleeding. For buccal administration, the medical preparation according to the invention comprises a peptide as the medical substance, used as antiviral agent and adjuvant, for example AdDP, or releasing factor for luteinisation and follicle stimulating hormones (Fertirelin, Lecirelin). The medical preparation according to the invention for local administration into an open wound comprises peptide as the medical substance used to stop bleeding (Terlipressin), and Dalargin for accelerating the wound healing, optionally AdDP for local stimulation of the immune system.
The enclosed
The conjugate of peptide with the material based on hyaluronan according to the invention was successfully prepared and tested by the authors in the applicant's facilities—Contipro a.s., Dolní Dobruč, CZ.
The fibre from the native HYA and nonwoven fabric from the native HYA were prepared according to the process described in the patent WO/2013/167098. The fibre from palmitoyl HYA was prepared according to the process described in the patent WO/2014/082611.
In the following examples, the term “equivalent (eq.)” relates to a repetitive unit of the respective form of hyaluronan. The percentage is per volume, if not stated otherwise.
The molecular weight of hyaluronan starting forms is the weight average molecular weight determined by the SEC-MALLS method.
In the examples, for the purposes of subsequent analysis only, norleucin, as the non-essential amino acid, was bound first to easily determine proportional occurrence of amino acids. However, norleucin bonding is not the necessary condition and is not intended to limit the scope of the invention.
1 m of the fibre of native HYA (12 mg, 0.03 mmol, Mw=3.10 g·mol−1) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. The solution of 3 eq. of Fmoc-Nle-OH, 3 eq. of OxymaPure and 0.3 eq. of DMAP in 0.5 ml anhydrous DMF was prepared outside the reactor; after dissolving all of the components 3 eq. of DIC were added to activate the carboxyl group of an amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours and it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml DMF, 3×1.5 ml DCM, 3×1.5 ml IPA, 3×1.5 ml DCM, 3×1.5 ml DEE.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution S=0.01862 mmol/g.
1 m of the fibre of Fmoc-Nle-O-HYA prepared according to the Example 1 was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. Fmoc protecting group was cleaved off by means of adding 1.5 ml of 20% solution of piperidine in DMF into the reactor to the fibre. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the time of cleavage to 20 min and then it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The reaction is quantitative. Releasing of the amino group was confirmed by performing the ninhydrin confirmation reaction (Kaiser test).
1 m of fibre of native HYA (12 mg, 0.03 mmol, Mw=3.105 g·mol−1) was placed into a 2 ml syringe reactor equipped with a frit, the fibre was repeatedly washed with THF. A solution of 3 eq. of Fmoc-Nle-OH, 3 eq. of OxymaPure and 0.3 eq. of DMAP in 0.5 ml THF; after dissolving all the components 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor with the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours and it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of THF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 31.5 ml of DCM, 31.5 ml of DEE. The yield of the condensation reaction was determined by Fmoc-release test as the substitution S0,01759 mmol/g.
1 m of the fibre of native HYA (12 mg, 0.03 mmol, Mw=3.105 g·mol−1) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 1 eq. of Fmoc-Nle-OH, 1 eq. of OxymaPure, and 0.3 eq. of DMAP in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all of the components 1 eq. of DIC was added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° ° C. for the next 20 hours and it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution S=0.01804 mmol/g.
1 m of H-Nle-O-HYA prepared according to the Example 2 was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. The solution of 3 eq. of Fmoc-Lys(Boc)-OH, and 3 eq. of OxymaPure in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all of the components 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours and it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. The Fmoc protecting group was cleaved off by means of adding 1.5 ml of 20% solution of piperidine in DMF into the reactor with the fibre. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the cleavage time to 20 min and then it was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. This procedure was repeated 4 times.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The product composition (nfound) was confirmed by amino acids analysis as presented in Table 2. It is a serial synthesis performed by a step-by-step method; however, this procedure was repeated for all said derivatives. The individual rows show the composition of the prepared conjugate after finishing said cycle; i.e., after finishing the procedure described in Example 3 the product having the composition described in the first row is obtained. Then the procedure is repeated, and the product described in the second row is obtained, etc.
1 m of H-Nle-O-HYA prepared according to the Example 2 was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. The solution of 3 eq. of Fmoc-Lys(Fmoc)-OH, and 3 eq. of OxymaPure in 0.5 ml anhydrous DMF was prepared outside the reactor; after dissolving all the components 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor with the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours. The reaction was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. The Fmoc protecting group was cleaved off by means of adding 1.5 ml of 20% solution of piperidine in DMF into the reactor with the fibre. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the cleavage time to 20 min. The reaction was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. This procedure was repeated 2 times.
The reaction was monitored by the Fmoc-release test. The yield was determined by the Fmoc-release test. The composition of the product, shown in
1 m of H-Nle-O-HYA prepared according to the Example 2 was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of Fmoc-Lys(Boc)-OH, and 3 eq. of OxymaPure in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all of the components 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours. The reaction was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. Cleavage of Fmoc protecting group was performed by adding 1.5 ml of 20% solution of piperidine in DMF into the reactor to the fibre. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the cleavage time to 20 min and it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. This procedure was repeated 7 times for Fmoc-Ala-OH.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The product composition was confirmed by an amino acids analysis as the proportional occurrence of individual amino acids. The purity of the material was determined by means of MS-HPLC after degradation of the material. The results of the individual analysis are shown in the following Table 4:
1 m of the fibre from palmitoyl HYA (15 mg, 0.03 mmol, Mw=3.105 g·mol-) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of Fmoc-Nle-OH, and 3 eq. of OxymaPure and 0.3 eq. of DMAP in 0.5 ml anhydrous DMF was prepared outside the reactor; after dissolving all of the components, 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours and it was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution S=0.01029 mmol/g.
1 m of Fmoc-Nle-O-palmitoylHYA prepared according to Example 8 was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. Fmoc protecting group was cleaved off by means of adding 1.5 ml of 20% solution of piperidine in DMF into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for 5 min. The reaction was repeated while extending the time of cleavage to 20 min and then it was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The reaction is quantitative. Releasing of the amino group was confirmed by performing the ninhydrin confirmation reaction (Kaiser test).
1 m of H-Nle-O-palmitoylHYA prepared according to the Example 9 was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of Fmoc-Lys(Boc)-OH, and 3 eq. of OxymaPure in 0.5 ml anhydrous DMF was prepared outside the reactor; after dissolving all of the components 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours and it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. Cleavage of Fmoc protecting group was performed by adding 1.5 ml of 20% solution of piperidine in DMF into the reactor to the fibre. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the cleavage time to 20 min and then it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. This procedure was repeated 4 times.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The composition of the product (nfound) was confirmed by amino acid analysis, as presented in Table 5 below. It is a serial synthesis performed by the step-by-step method; however, this procedure was repeated for all the derivatives. The individual rows show the composition of the prepared conjugate after finishing the said cycle; i.e., after finishing the procedure described in the Example 3 the product having the composition described in the first row is obtained. Then the procedure is repeated, and the product described in the second row is obtained, etc.
1 m of H-Nle-O-palmitoylHYA prepared according to the Example 9 was placed into the 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of Fmoc-Lys(Boc)-OH, and 3 eq. of OxymaPure in 0.5 ml anhydrous DMF was prepared outside the reactor; after dissolving all components, 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours. The reaction was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. Cleavage of Fmoc protecting group was performed by adding 1.5 ml of 20% solution of piperidine in DMF into the reactor to the fibre. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the cleavage time to 20 min. The reaction was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DMF. This procedure was repeated 2 times.
The reaction was monitored by Fmoc-release test. The yield was determined by Fmoc-release test. The composition of the product, shown in
1 m of formylHYA fibre (11 mg, 0.028 mmol, Mw=3.105 g·mol−1) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. The solution of 3 eq. of Fmoc-Lys-NH2 in 0.5 ml of anhydrous DMF was prepared outside the reactor and transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours. Then 3 eq. of picBH3 were added and the reaction proceeded at the temperature of 18 to 23° C. for the next 24 hours, then it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE. Cleavage of Fmoc protecting group was performed by adding 1.5 ml of 20% solution of piperidine in DMF into the reactor to the solution. The reaction proceeded for 5 min at the temperature of 18 to 23° C. The reaction was repeated while extending the cleavage time to 20 min and then it was terminated by filtering the reaction solution off. The fibre was then washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
Releasing of the amino group was confirmed by performing a ninhydrin confirmation reaction (Kaiser test).
1 m of native HYA fibre (12 mg, 0.03 mmol, Mw=3.105 g·mol-) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of a peptide having the appropriate sequence, 3 eq. of OxymaPure in 0.3 eq. of DMAP in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all the components 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours. The reaction was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The composition of the product was confirmed by amino acid analysis as the proportion of individual amino acids. The purity of the material was determined by means of MS-HPLC after the degradation of the material. The results of the individual analyses are shown in the following Table 7:
5 squares of the side of 5 mm made of nonwoven fabric of native HYA (10.5 mg, 0.03 mmol, Mw=1.04×106 g·mol−1) were placed into a 2 ml syringe reactor equipped with a frit; the material was repeatedly washed with DMF. A solution of 3 eq. of a peptide having the appropriate sequence and 3 eq. of OxymaPure in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all of the components, 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the material. The reaction proceeded at the temperature of 18 to 23° C. for the next 20 hours. The reaction was terminated by filtering the reaction solution off. Then the fabric was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The composition of the product was confirmed by an amino acid analysis as the proportional occurence of the individual amino acids. The purity of the material was determined by means of MS-HPLC after the degradation of the material. The results of the individual analysis are presented in the following Table 8:
1 m of native HYA fibre (12 mg, 0.03 mmol, Mw=3.105 g·mol−1) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of the peptide Fmoc-(VPGLG)2-OH, 3 eq. of OxymaPure, and 0.3 eq. of DMAP in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all of the components, 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° C. for further 20 hours, and it was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The composition of the product was confirmed by an amino acid analysis as the proportional occurrence of the individual amino acids. The purity of the material was determined by means of MS-HPLC after the degradation of the material. The results of the individual analysis are shown in the following Table 9:
1 m of native HYA fibre (12 mg, 0.03 mmol, Mw=3.105 g·mol−1) was placed into a 2 ml syringe reactor equipped with a frit; the fibre was repeatedly washed with DMF. A solution of 3 eq. of the peptide Fmoc-Dalagrin, 3 eq. of OxymaPure, and 0.3 eq. of DMAP in 0.5 ml of anhydrous DMF was prepared outside the reactor; after dissolving all of the components, 3 eq. of DIC were added to activate the carboxyl group of the amino acid. This solution was transferred into the reactor to the fibre. The reaction proceeded at the temperature of 18 to 23° ° C. for further 20 hours, and it was terminated by filtering the reaction solution off. Then the fibre was washed with 3×1.5 ml of DMF, 3×1.5 ml of DCM, 3×1.5 ml of IPA, 3×1.5 ml of DCM, 3×1.5 ml of DEE.
The yield of the condensation reaction was determined by Fmoc-release test as the substitution in mmol/g. The composition of the product was confirmed by an amino acid analysis as the proportional occurrence of the individual amino acids. The purity of the material was determined by means of MS-HPLC after the degradation of the material. The results of the individual analysis are shown in the following Table 10:
The fibre of native HYA comprising RGD motif, prepared according to the procedure described in Example 14, and control fibres were cut into 1 cm pieces and transferred onto a non-adhesive panel with 24 wells. Primary human fibroblasts (NHDF) were pre-marked with the fluorescent dye DiI (Exmax/Emmax 549/565) and inoculated, in the amount of 105 cells, into the wells filled with the tested samples. Then the panel was shaken by a shaker (5 hrs/160 rpm) to keep the cells in suspension, under cultivation conditions (37° C., 5% CO2). After 24 h of cultivation the fibres were transferred into a well with fresh cultivation medium. Then the cells were observed and detected by fluorescent microscope Nikon Ti-Eclipse with the use of TRITC filter (Exmax/Emmax, 549/565). The fibroblasts proliferation was monitored for 7 days of cultivation.
Human dermal fibroblasts adhered and proliferated during the time only on the fibre with the peptide H-Arg-Gly-Asp-Ahx-Ahx-Nle-OH bonded to HYA via 2 units of 6-aminohexanoic acid that form a firm and elastic linker and thus make the RGD peptide accessible for cell adhesion receptors. On the contrary, the peptide H-Ahx-Ahx-Arg-Gly-Asp-Nle-OH, as well as the linking of peptides H-Arg-Gly-Asp-Gly-Gly-Gly-Nle-OH and H-Gly-Gly-Gly-Arg-Gly-Asp-Nle-OH via triglycine linker, did not support the cell adhesion, as can be seen in
Nonwoven fabric of HYA with an anchored peptide H-Arg-Gly-Asp-Ahx-Ahx-Nle-OH prepared according to the procedure described in Example 14, and a control fabric were cut into squares with a side length of 0.5 cm, and were transferred onto 24 wells plate of non-adhesive panel. Primary human fibroblasts (NHDF) were pre-marked with the fluorescent dye DiI (Exmax/Emmax 549/565) and inoculated, in the amount of 105 cells, into the wells filled with the tested samples. Then the panel was shaken by a shaker (5 hrs/160 rpm) to keep the cells in suspension, under cultivation conditions (37° C., 5% CO2). After 24 h of cultivation the fabric was transferred into a well with a fresh culture media. Then the cells were observed and detected by the fluorescent microscope Nikon Ti-Eclipse with the use of TRITC filter (Exmax/Emmax, 549/565). The fibroblasts proliferation was monitored for 7 days of cultivation, as can be seen in
NHDF adhered uniformly onto the fabric surface and after 48 hours they elongated in a characteristic manner.
The new medical preparation with a carrier based on hyaluronan and its derivatives can be used as a suitable drug form for treatment with the attached medical substance. This new dosage form brings an improved prolonged activity of the medical substance bound on the solid carrier of the complex system. Suitable forms of hyaluronan with the bound medical substances can be used in human and veterinary medicine.
| Number | Date | Country | Kind |
|---|---|---|---|
| PV 2016-826 | Dec 2016 | CZ | national |
This application is the National Stage of International Application No. PCT/CZ2017/050061, filed on 22 Dec. 2016, which claims priority to and all advantages of CZ Application No. PV2016-826, filed on 22 Dec. 2016, the content of which is hereby incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CZ2017/050061 | 12/19/2017 | WO | 00 |
